Search - tctmd.com

Displaying 1 - 20 of 731

Sort: Relevancy | Date

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for November 2025

Caitlin E. Cox

December 01, 2025

News Daily News

Asundexian Reduces Recurrent Stroke Without Bleeding Risk: OCEANIC-STROKE

Michael O'Riordan

November 24, 2025

News Daily News

Fish Oil Halves CV Risk in Patients on Dialysis: PISCES

Yael L. Maxwell

November 10, 2025

News Conference News AHA 2025

Stopping DOACs After Successful AF Ablation Feasible in Low-risk Patients: OCEAN

Michael O'Riordan

November 08, 2025

News Conference News AHA 2025

Evolocumab Cuts MACE Risk in Patients Without Prior MI, Stroke: VESALIUS-CV

Michael O'Riordan

November 08, 2025

News Opinion CV Team Dispatch

October 2025 Dispatch for the CV Team

L.A. McKeown

October 25, 2025

News Daily News

Semaglutide’s CV Effects Only Partially Tied to Weight Loss: SELECT Analysis

Yael L. Maxwell

October 24, 2025

News Daily News

Slight Gain in Stroke Protection Seen With DAPT in ViV TAVI

L.A. McKeown

October 09, 2025

News Daily News

Evolocumab Wins for Primary Prevention in VESALIUS-CV

L.A. McKeown

October 03, 2025

News Daily News

Risk Factors Present in Nearly All Patients Who Develop CVD

Michael O'Riordan

October 02, 2025

News Opinion CV Team Dispatch

September 2025 Dispatch for the CV Team

L.A. McKeown

September 30, 2025

News Daily News

CVD Still the Leading Cause of Death and Disease Globally

Michael O'Riordan

September 24, 2025

News Daily News

Better Outcomes and Lower Cost with Bariatric Surgery Over GLP-1s

Michael O'Riordan

September 18, 2025

News Conference News ESC 2025

High hs-CRP Linked to More CVD Events in Women Lacking Traditional Risk Factors

Caitlin E. Cox

August 29, 2025

News Daily News

HOPE Supports IV Alteplase in Late Window After Acute Ischemic Stroke

Todd Neale

August 11, 2025

News Daily News

Glipizide, Commonly Used Sulfonylurea, Linked to Greater CV Risks

Michael O'Riordan

August 01, 2025

News Daily News

Tirzepatide Matches Dulaglutide in Large CV Outcomes Trial: SURPASS-CVOT

Michael O'Riordan

July 31, 2025

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for July 2025

Caitlin E. Cox

July 31, 2025

News Opinion CV Team Dispatch

July 2025 Dispatch for the CV Team

L.A. McKeown

July 24, 2025

News Conference News SCCT 2025

AI-Based Coronary Plaque Analysis Can Inform Management Beyond CCTA: DECIDE Registry

Yael L. Maxwell

July 21, 2025

Advertisement

TCTMD’s Top 10 Most Popular Stories for November 2025

Asundexian Reduces Recurrent Stroke Without Bleeding Risk: OCEANIC-STROKE

Fish Oil Halves CV Risk in Patients on Dialysis: PISCES

Stopping DOACs After Successful AF Ablation Feasible in Low-risk Patients: OCEAN

Evolocumab Cuts MACE Risk in Patients Without Prior MI, Stroke: VESALIUS-CV

October 2025 Dispatch for the CV Team

Semaglutide’s CV Effects Only Partially Tied to Weight Loss: SELECT Analysis

Slight Gain in Stroke Protection Seen With DAPT in ViV TAVI

Evolocumab Wins for Primary Prevention in VESALIUS-CV

Risk Factors Present in Nearly All Patients Who Develop CVD

September 2025 Dispatch for the CV Team

CVD Still the Leading Cause of Death and Disease Globally

Better Outcomes and Lower Cost with Bariatric Surgery Over GLP-1s

High hs-CRP Linked to More CVD Events in Women Lacking Traditional Risk Factors

HOPE Supports IV Alteplase in Late Window After Acute Ischemic Stroke

Glipizide, Commonly Used Sulfonylurea, Linked to Greater CV Risks

Tirzepatide Matches Dulaglutide in Large CV Outcomes Trial: SURPASS-CVOT

TCTMD’s Top 10 Most Popular Stories for July 2025

July 2025 Dispatch for the CV Team

AI-Based Coronary Plaque Analysis Can Inform Management Beyond CCTA: DECIDE Registry

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content